On September 13th, the WHO South-East Asia Regional Committee announced a new commitment to eliminate measles and control rubella by 2020.

From 19-22 February 2013, Sabin Executive Vice-President Dr. Ciro de Quadros and Program Officer Brian Shaw participated in the SEARO Regional Consultation on Measles Elimination and Rubella/CRS Control, held in Kathmandu, Nepal. As a member of the Measles Rubella Initiative (MRI), Sabin is committed to the elimination of measles, rubella & congenital rubella syndrome (CRS).
Rwanda’s measles-rubella vaccination campaign, which is being launched today, is the beginning of an effort to vaccinate more than 700 million children under 15 years of age against two disabling and deadly diseases.

Rubella and CRS Global Advocacy

Rubella, also known as German Measles, is an often mild disease whose symptoms can range from a fever and rash to signs too mild to detect.  When contracted by a pregnant woman in her first 20 weeks, however, rubella can lead to Congenital Rubella Syndrome (CRS) in the fetus, and the effects can be devastating. The disease can cause severe growth and mental retardation, deafness and other developmental problems when the fetus becomes infected. Though the burden of CRS is not well documented, the WHO estimates that in developing countries alone 100,000 cases of CRS occur each year.

Vaccine Advocacy & Education

The Vaccine Advocacy and Education program at Sabin is dedicated to reducing the burden of preventable diseases by bringing together key stakeholders and leaders in government, private sector and civil society in order to foster cooperation, share information and best practices, and develop improved vaccine policy and access.

One year ago at the GAVI Alliance pledge conference, partners exceeded expectations by pledging $4.3 billion dollars.

Dr. de Quadros and Hotez featured in Vaccine special supplement!

Pages

Subscribe to RSS - rubella